Subjects with Hepatitis C Virus (HCV) infection, genotype 1 or 4 and with hepatocellular
carcinoma (HCC) and a complete response to HCC therapy will be randomised to immediate or
delayed (6 months) HCV therapy with Elbasvir (MK-8742) and Grazoprevir (MK-5172) [EBR/GZR].
Phase:
Phase 3
Details
Lead Sponsor:
Bayside Health
Collaborators:
Austin Hospital, Melbourne Australia Merck Sharp & Dohme Corp.